A haplotype of the catalase gene confers an increased risk of essential hypertension in Chinese Han

Human Mutation

Volumn 31, Issue 3, 2010, Pages 272-278

  Wang, Zhimin ^a,b   Li, Yanping ^a   Wang, Beilan ^b   He, Yungang ^a   Wang, Yi ^a   Xi, Huifeng ^c   Li, Yifeng ^a   Wang, Ying ^b,b   Zhu, Dingliang ^d   Jin, Jianzhong ^a   Huang, Wei ^b   Jin, Li ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Allelic expression imbalance; CAT; Catalase; Essential hypertension

Indexed keywords

CATALASE; LUCIFERASE;

5' UNTRANSLATED REGION; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CATH1 GENE; CATH2 GENE; CELL LINE; CHINESE; CONTROLLED STUDY; ESSENTIAL HYPERTENSION; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC RISK; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HOMOZYGOTE; HUMAN; HUMAN CELL; HYPOTHESIS; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION;

AGED; ALLELES; BASE SEQUENCE; CATALASE; CHINA; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; OXIDATIVE STRESS; PROTEIN STRUCTURE, SECONDARY; RISK;

EID: 77149166593     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.21185     Document Type: Article

References (34)

1. Agar NS, Sadrzadeh SM, Hallaway PE, Eaton JW. 1986. Erythrocyte catalase. A somatic oxidant defense? J Clin Invest 77:319-321.
2. Bai J, Cederbaum AI. 2003. Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53. J Biol Chem 278:4660-4667.
3. Behl C, Davis JB, Lesley R, Schubert D. 1994. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77:817-827.
4. Busciglio J, Yankner BA. 1995. Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitro. Nature 378:776-779.
5. Chalmers J, MacMahon S, Mancia G, Whitworth J, Beilin L, Hansson L, Neal B, Rodgers A, Ni Mhurchu C, Clark T. 1999. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 21:1009-1060.
6. Cirulli ET, Goldstein DB. 2007. In vitro assays fail to predict in vivo effects of regulatory polymorphisms. Hum Mol Genet 16:1931-1939.
7. Consortium WTCC. 2007. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661-678.
8. Davey Smith G, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day IN, Ebrahim S. 2005. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality. Arterioscler Thromb Vasc Biol 25:1051-1056.
9. Devlin B, Roeder K. 1999. Genomic control for association studies. Biometrics 55:997-1004.
10. Ehret GB, Morrison AC, O'Connor AA, Grove ML, Baird L, Schwander K, Weder A, Cooper RS, Rao DC, Hunt SC, Boerwinkle E, Chakravarti A. 2008. Replication of the Wellcome Trust genome-wide association study of essential hypertension: the Family Blood Pressure Program. Eur J Hum Genet 16:1507-1511.
11. Finkel T. 1998. Oxygen radicals and signaling. Curr Opin Cell Biol 10:248-253.
12. Forsberg L, Lyrenas L, de Faire U, Morgenstern R. 2001. A common functional C-T substitution polymorphism in the promoter region of the human catalase gene influences transcription factor binding, reporter gene transcription and is correlated to blood catalase levels. Free Radic Biol Med 30:500-505.
13. Griendling KK, Alexander RW. 1997. Oxidative stress and cardiovascular disease. Circulation 96:3264-3265.
14. Gu D, Reynolds K, Wu X, Chen J, Duan X, Muntner P, Huang G, Reynolds RF, Su S, Whelton PK, He J; InterASIA Collaborative Group. The International Collaborative Study of Cardiovascular Disease in ASIA. 2002. Prevalence, awareness, treatment, and control of hypertension in china. Hypertension 40:920-927.
15. Halliwell B. 1989. Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br J Exp Pathol 70:737-757.
16. Halliwell B. 1993. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 23(Suppl 1):118-126.
17. Halliwell B. 2003. Oxidative stress in cell culture: an under-appreciated problem? FEBS Lett 540:3-6.
18. Jiang Z, Akey JM, Shi J, Xiong M, Wang Y, Shen Y, Xu X, Chen H, Wu H, Xiao J, Lu D, Huang W, Jin L. 2001. A polymorphism in the promoter region of catalase is associated with blood pressure levels. Hum Genet 109:95-98.
19. Katan MB. 2004. Apolipoprotein E isoforms, serum cholesterol, and cancer. 1986. Int J Epidemiol 33:9. First published in The Lancet 1986; i:507-508. Reprinted with permission.
20. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. 2005. Global burden of hypertension: analysis of worldwide data. Lancet 365:217-223.
21. Khullar M, Relan V, Sehrawat BS. 2004. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 43:e7-8; author reply e7-8.
22. Kunz R, Kreutz R, Beige J, Distler A, Sharma AM. 1997. Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 30:1331-1337.
23. Lacy F, O'Connor DT, Schmid-Schonbein GW. 1998. Plasma hydrogen peroxide production in hypertensives and normotensive subjects at genetic risk of hypertension. J Hypertens 16:291-303.
24. Little J, Khoury MJ. 2003. Mendelian randomisation: a new spin or real progress? Lancet 362:930-931.
25. Mates JM, Perez-Gomez C, Nunez de Castro I. 1999. Antioxidant enzymes and human diseases. Clin Biochem 32:595-603.
26. Padmanabhan S, Melander O, Hastie C, Menni C, Delles C, Connell JM, Dominiczak AF. 2008. Hypertension and genome-wide association studies: combining high fidelity phenotyping and hypercontrols. J Hypertens 26:1275-1281.
27. Rao GN, Berk BC. 1992. Active oxygen species stimulate vascular smooth muscle cell growth and proto-oncogene expression. Circ Res 70:593-599.
28. Redon J, Oliva MR, Tormos C, Giner V, Chaves J, Iradi A, Saez GT. 2003. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 41:1096-1101.
29. Rhee SG. 1999. Redox signaling: hydrogen peroxide as intracellular messenger. Exp Mol Med 31:53-59.
30. Rosenfeld ME. 1998. Inflammation, lipids, and free radicals: lessons learned from the atherogenic process. Semin Reprod Endocrinol 16:249-261.
31. Sozmen B, Delen Y, Girgin FK, Sozmen EY. 1999. Catalase and paraoxonase in hypertensive type 2 diabetes mellitus: correlation with glycemic control. Clin Biochem 32:423-427.
32. Sun A, Ge J, Siffert W, Frey UH. 2005. Quantification of allele-specific G-protein beta3 subunit mRNA transcripts in different human cells and tissues by Pyrosequencing. Eur J Hum Genet 13:361-369.
33. Tobin MD, Minelli C, Burton PR, Thompson JR. 2004. Commentary: development of Mendelian randomization: from hypothesis test to "Mendelian deconfounding." Int J Epidemiol 33:26-29.
34. Yan H, Yuan W, Velculescu VE, Vogelstein B, Kinzler KW. 2002. Allelic variation in human gene expression. Science 297:1143.